Lannett Competitors and Similar CompaniesClear all
Lannett's competitors and similar companies include Sarepta Therapeutics, PTC Therapeutics, Ionis Pharmaceuticals and United Therapeutics.
 Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. |  PTC Therapeutics PTC Therapeutics is a biopharmaceutical company that engages in the discovery, development, and commercialization of small-molecule drugs. |  Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. |  United Therapeutics United Therapeutics is a biotechnology company that develops and manufactures pharmaceutical products for pulmonary arterial hypertension and certain cancers. | ||
Founding Date | Founding Date 1942 | Founding Date 1980 | Founding Date 1998 | Founding Date 1989 | Founding Date 1996 |
Type | Type Subsidiary | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Trevose, US HQ Philadelphia, US Seymour, US | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US | Locations South Plainfield, US HQ | Locations Silver Spring, US HQ Durham, US Jacksonville, US Manchester, US Melbourne, US Washington, US | |
Employees | Employees 484 | Employees 1,31413% increase | Employees 75448% increase | Employees 1,40231% increase | Employees 1,16819% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 12.4 b | Valuation ($) 3.3 b | Valuation ($) 6.3 b | Valuation ($) 15.7 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $340.6m (FY, 2022) | Revenue (est.) $2.2b (FY, 2025) | Revenue (est.) $1.7b (FY, 2025) | Revenue (est.) $943.7m (FY, 2025) | Revenue (est.) $3.2b (FY, 2025) |
Cost of goods | Cost of goods $294.5m (FY, 2022) | Cost of goods $25.5m (FY, 2025) | Cost of goods N/A | Cost of goods $15.9m (FY, 2025) | Cost of goods $384.4m (FY, 2025) |
Gross profit | Gross profit $33.2m (FY, 2022) | Gross profit $2.2b (FY, 2025) | Gross profit N/A | Gross profit $927.8m (FY, 2025) | Gross profit $2.8b (FY, 2025) |
Net income | Net income ($231.6m) (FY, 2022) | Net income ($713.4m) (FY, 2025) | Net income $682.6m (FY, 2025) | Net income ($381.4m) (FY, 2025) | Net income $1.3b (FY, 2025) |
Operating ⚠ | |||||
Facility Space, sq. ft. | Facility Space, sq. ft. 400 k (Aug, 2025) | Facility Space, sq. ft. 431.6 k (FY, 2021) | Facility Space, sq. ft. N/A | Facility Space, sq. ft. N/A | Facility Space, sq. ft. N/A |
For sources of this data, please see the company profile
View Company Profiles
Sarepta Therapeutics
HQ
Cambridge, US
Employees
1,314↑ 13% increase
Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.
View companyPTC Therapeutics
HQ
South Plainfield, US
Employees
754↑ 48% increase
PTC Therapeutics is a biopharmaceutical company that engages in the discovery, development, and commercialization of small-molecule drugs.
View companyIonis Pharmaceuticals
HQ
Carlsbad, US
Employees
1,402↑ 31% increase
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
View companyUnited Therapeutics
HQ
Silver Spring, US
Employees
1,168↑ 19% increase
United Therapeutics is a biotechnology company that develops and manufactures pharmaceutical products for pulmonary arterial hypertension and certain cancers.
View company